XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ
May 14, 2024 07:30 ET
|
XOMA Corporation
EMERYVILLE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today that members of its Executive Team will participate in the H.C....
XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities
May 09, 2024 07:30 ET
|
XOMA Corporation
Earned $9 million milestone upon U.S. Food and Drug Administration’s approval of Day One’s OJEMDA™ (tovorafenib); XOMA is entitled to receive a mid-single digit royalty on OJEMDA™ sales Acquired...
XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2%
April 30, 2024 07:30 ET
|
XOMA Corporation
Organon, a global women’s healthcare company, initiated XACIATO™ commercial activities in the fourth quarter of 2023 XOMA further expands its late-stage portfolio with synthetic royalty and milestone...
XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)
April 25, 2024 07:30 ET
|
XOMA Corporation
XOMA is entitled to a mid-single digit royalty on global OJEMDA™ sales First and only FDA-approved type II RAF inhibitor for patients with relapsed or refractory pLGG harboring a BRAF fusion or...
XOMA Corporation Announces Closing of Tender Offer
April 03, 2024 09:00 ET
|
XOMA Corporation
XOMA completes acquisition of Kinnate.
XOMA Declares Quarterly Preferred Stock Dividends
March 21, 2024 07:30 ET
|
XOMA Corporation
April 2024 quarterly dividend
XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.
March 19, 2024 16:05 ET
|
XOMA Corporation
Pricing of Kinnate acquisition
XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value
March 08, 2024 07:30 ET
|
XOMA Corporation
Raised up to $140 million of non-dilutive non-recourse capital through a royalty-backed loan related to VABYSMO® from funds managed by Blue Owl Capital Received $15.5 million in cash payments related...
XOMA to Present at Upcoming Investor Conferences in March
February 28, 2024 07:30 ET
|
XOMA Corporation
EMERYVILLE, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today members of its Executive Team will participate at the following...
XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right
February 16, 2024 08:00 ET
|
XOMA Corporation
XOMA enters agreement to acquire Kinnate for cash and CVR; Expects to add $9.5M cash to balance sheet upon completion of acquisition